Measurement of Adherence to ART in HIV-Infected Children in Uganda (The CHARTA Study)

HIV Infections Clinical Trial

Official title:

Measurement of Adherence to ART in HIV-Infected School-Aged Children in Uganda

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00868257
• Other study ID #: R21MH083306
• Secondary ID: R21MH083306
• Status: Completed
• Phase: N/A
• First received: March 23, 2009
• Last updated: January 11, 2012
• Start date: July 2008
• Est. completion date: May 2010

Study information

• Verified date: January 2012
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

This study will compare methods of determining whether HIV-infected children take their medications.

Description:

HIV is a virus that weakens people's immune systems and can cause AIDS. Antiretroviral therapy (ART) is a treatment for HIV that combines different types of antiretroviral medications, but it must be taken throughout a person's life without missing doses to be effective. When people do miss doses, the HIV virus has an opportunity to develop resistance to the medications, making them less effective in the future. Reports indicate that as many as 50% of children infected with HIV who are living in resource-limited countries regularly miss doses of their ART. This study will test different methods for determining children's rates of adherence to ART medications. This will both define the exact magnitude of the problem and direct future efforts in increasing ART adherence in children.

Participation in this study will last 12 months. All children enrolled will undergo a series of assessments of medication adherence. At baseline and every month over the course of the study, researchers will make unannounced home visits to measure the amount of medicine that remains untaken by participants and to record how many times the electronic cap on participants' medication bottles have been removed. Participants with cell phones will also receive monthly phone calls during which they will be asked to measure the amount of their medicine that remains untaken. At study entry and after 6 and 12 months, researchers will also examine child participants' medical records and the results of their regularly scheduled blood tests. At these blood tests, an additional half teaspoon of blood, which may be used in future testing, will be collected and stored by the researchers. After 3, 6, 9, and 12 months, researchers will request to collect hair samples from child participants to test levels of HIV medications in the hair, but participation in this part of the study is optional.

Assessments of reasons for medication adherence will also be performed. At study entry and after 3, 6, 9, and 12 months, children and their parents will complete questionnaires about their understanding of HIV medicines and HIV infection, motivation for the child to take medications, behaviors related to taking medications, and basic personal information. One and 7 months after study entry, some parent participants will also complete interviews with study staff about giving HIV medicines to their children.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: May 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 10 Years

Eligibility

Inclusion Criteria:

• HIV-infected

• Receiving highly active antiretroviral therapy (HAART) through the Children's HIV/AIDS Care Clinic

• Resident in the Mbarara district, defined as living within 30 km or a 2-hour driving radius of the city of Mbarara

• Plans to stay within the Mbarara district for the next year

Exclusion Criteria:

• Attendance at a boarding school

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• HIV
• HIV Infections

Locations

Country	Name	City	State
Uganda	Mbarara University of Science and Technology	Mbarara

Sponsors (2)

Lead Sponsor	Collaborator
Massachusetts General Hospital	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median antiretroviral therapy (ART) adherence levels for multiple measures of adherence		Measured monthly for 12 months	No
Secondary	Correlation of median ART adherence levels among the multiple measures and with HIV RNA		Measured after 1 year	No